Shaping Innovation

Mr. Bailly has served as Chairman of the Company since October 2006 and as Chief Executive Officer and a director since January 1, 1995. He joined the Company in 1988 and served as a Division Manager (1989-1992), General Manager Northeast Operations (1992-1994), Vice President of Operations (1994-1995), and as its President (1995-2024). From 1984 through 1988, Mr. Bailly, a certified public accountant, was employed by Coopers & Lybrand. Mr. Bailly is a member of World Presidents’ Organization. As a result of these and other professional experiences, Mr. Bailly possesses particular knowledge and experience in operations, accounting, finance, mergers and acquisitions, and executive leadership within a manufacturing environment that strengthen the Board’s collective qualifications, skills, and experience.

Mr. Rock initially joined UFP Technologies in 1991 and served as Director of Sales and Marketing for the company’s Molded Fiber division. From May 1999 through October 2000, Mr. Rock served as Vice President of Sales and Business Development at Esprocket, an internet start-up company. Mr. Rock rejoined UFP in April 2001 as Vice President of Sales and Marketing for the company’s Molded Fiber division and later served as Vice President of Sales and Marketing for the entire company from May 2002 to June 2014. In June 2014, Mr. Rock was promoted to Senior Vice President of Sales and Marketing. In January 2020, he was named General Manager, Medical, and in June 2021, the Board of Directors appointed him President of MedTech. In February 2024, Mr. Rock was appointed President of the company. Since 2016, he has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.

Mr. Lataille joined UFP Technologies in November 1997 as its Chief Financial Officer. Prior to joining the company, Mr. Lataille served as Vice President, Treasurer and Chief Financial Officer of Little Switzerland, Inc., from 1991 through October 1997. He also served as interim President and Chief Executive Officer of Little Switzerland from October 1994 through October 1995. From 1984 to 1991, Mr. Lataille, a certified public accountant, was employed by Coopers & Lybrand.

Mr. Litterio joined UFP Technologies in November 2017 as its first General Counsel and Senior Vice President of Human Resources. From 1989 until 2017, Mr. Litterio was engaged in the private practice of law at Ruberto, Israel & Weiner, PC, a Boston-based law firm, where he focused on complex business litigation and employment law. From 2005 until 2017, he served as the firm’s managing partner, and from 2000 until 2005, he was the chair of the firm’s litigation department.

Mr. Cardin joined UFP Technologies in 2019 as Chief Operating Officer of the MedTech business. In June of 2021, the Board of Directors promoted him to Vice President. Prior to joining the UFP, Mr. Cardin spent 27 years in a variety of leadership positions with medical device OEMs and contract manufacturers. Just prior to joining the company, Mr. Cardin served as President of Viant Medical, a Tier 1 contract manufacturer of medical components and devices. Before entering the medical manufacturing field, Mr. Cardin, a graduate of the United States Military Academy, served as a Captain in the United States Army.

Mr. Holt joined UFP Technologies in 2018 as General Manager of our Advanced Components business. In June of 2021, he was appointed Vice President by the Board of Directors and in February of 2024 he was promoted to Chief Commercial Officer of the company. From 2004-2018, Mr. Holt held a number of leadership positions at a Fortune 200 company, Illinois Tool Works, where he ultimately became Vice President and General Manager of a $100+ million business unit.

Ms. Feldmann has served as one of our directors since June 2017. In March 2022, Ms. Feldmann joined the board of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office real estate investing trust focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations. She serves on the Alexandria board’s Science and Technology Committee. Ms. Feldmann served on the board of Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, where she also chaired the Frequency Audit Committee from September 2020 until November 2023 when Frequency was combined with Korro Bio(Nasdaq: KRRO) in a reverse merger.

Since 2005, Ms. Feldmann has served on the board of directors of STERIS PLC (NYSE: STE), a provider of infection prevention, decontamination, and health science technologies, products and services. She chairs the STERIS Nominating & Governance Committee and previously chaired and is a current member of the Audit Committee. She also previously served as a member of the STERIS Compliance and Technology Committee.

Ms. Feldmann also served from 2003 to 2018 on the board of directors of Hanger Inc. (NYSE: HNGR), a provider of orthotic and prosthetic services and products, and the largest orthotic and prosthetic managed care network in the U.S. Ms. Feldmann served on the Audit Committee, including as Chair of the Audit Committee, the Compensation Committee and the Quality and Technology Committee of Hanger. From 2013 to 2023 Ms. Feldmann served on the board of trustees and was a member and previously chaired the Finance Committee of Falmouth Academy, an academically rigorous, co-ed college preparatory day school for grades 7 to 12.

Ms. Feldmann previously served as a director and chair of the Audit Committee and as a member of the Nominating and Governance, Compensation, and Quality and Technology Committees of Heartware International, Inc., a Nasdaq-listed medical device company, from 2012 until its acquisition by Medtronic in August 2016. Previously, Ms. Feldmann had a 29-year career in public accounting; she was Partner at KPMG LLP, holding various leadership roles in the firm’s Medical Technology and Health Care & Life Sciences industry groups and was National Partner-in-Charge of the Life Sciences practice for Coopers & Lybrand (now PricewaterhouseCoopers LLP), among other leadership positions she held during her career there.

Ms. Feldmann was a founding board member of Mass Medic, a Massachusetts trade association for medical technology companies, where she also served as treasurer and as a member of the board's Executive Committee during her tenure from 1997 to 2001.

Mr. Croteau has served as a director of the Company since December 2015. Currently, Mr. Croteau is a member of the board of directors of Corza Medical, a private equity-backed company that specializes in high performance wound closure products, biosurgical products and ophthalmic instrumentation. Mr. Croteau served as the CEO of Corza Medical from January of 2021 to January of 2023, when he retired. His prior company, Surgical Specialties Corporation, was acquired in January 2021 and was simultaneously combined with the Tachosil Business from Takeda Pharmaceuticals to form Corza Medical.

Since May 2019, Mr. Croteau has served on the board of directors of Resonetics, a privately held laser manufacturing services company providing micro components to global medical device companies. From October 2014 to March 2018 and from July 2020 to present, Mr. Croteau also served as a member of the board of directors of Inventus Power, a privately held, global manufacturer of custom battery packs, chargers and portable power supply systems.

Mr. Croteau was the Chief Executive Officer of Vention Medical from January 2011 until March 2017, when he resigned in connection with the acquisition of Vention Medical by Nordson Corporation and the divestiture of the Vention Device Manufacturing Services business unit to MedPlast Inc. Vention Medical provided component manufacturing, assembly, and design services for disposable medical devices. Prior to assuming his role with Vention Medical, Mr. Croteau was President of FlexMedical from July 2005 through December 2010. FlexMedical is the medical division of Flex, which provides manufacturing and supply chain services for disposable medical devices, medical equipment, and drug delivery devices.

From July 2004 to June 2005, Mr. Croteau served as the Executive Vice President and General Manager of Orthopedics for Accellent (renamed Lake Region Medical in 2014 and now a division of Integer), a manufacturer of specialty components and finished medical devices used in orthopedic, cardiology, and surgical devices. From August 1999 to June 2004, Mr. Croteau served as an executive at MedSource Technologies, which was merged in June 2004 with UTI Corporation to form Accellent. As Senior Vice President at MedSource Technologies, Mr. Croteau was responsible for sales, marketing, strategy and acquisitions. Prior to entering the medical device industry in 1999, Mr. Croteau spent the majority of his career in various roles at General Electric and working as a consultant for Booz & Company in Sydney, Australia. Mr. Croteau has a Bachelor of Science degree in mechanical engineering from the University of Vermont and a Master of Business Administration from Harvard Business School.

Mr. Hassett has served as a director of the Company since June 2022. Currently, Mr. Hassett is Senior Vice President and Chief Operating Officer for the Maxim Business at Analog Devices Inc.’s (“ADI”), where he leads strategic and operational integration of Maxim Inc., a business acquired by ADI in August 2021. Mr. Hassett brings extensive experience as a business leader, having run ADI’s largest revenue-generating business, and operational expertise by leveraging his previous Global Operations & Technology leadership, in addition to his various engineering management roles with ADI.

From December 2020 to July 2021, Mr. Hassett was Senior Vice President, Corporate Integration Management where he led significant efforts in M&A transactions and was responsible for developing strategies that drove the integration of multi-billion-dollar transactions from due diligence to fully integrated entities.

Previously, Mr. Hassett was Senior Vice President of Industrial and Consumer Group from November 2019 to December 2020, where he led growth initiatives which leveraged its extensive franchise capability in measurement, sensing and testing. He was Senior Vice President of Global Operations & Technology from May 2015 to November 2019, where he was instrumental in setting and executing the manufacturing strategy and creating a world-class, scalable supply chain to deliver outstanding quality for our customers. Mr. Hassett joined ADI in 1982 after graduating from the University of Limerick where he earned a Bachelor of Science degree in Manufacturing Engineering. Mr. Hassett also holds a Master of Business Administration from the University of Limerick.

Mr. Kozin has served as a director of the Company since 2006. In December 2020, Mr. Kozin joined the board of directors of Vascular Biogenics (Nasdaq: VBLT), a late stage oncology company, as Vice Chairman and was appointed Chairman in July 2021. In December 2022, Mr. Kozin transitioned to the board of directors from the strategic advisory board of Healthcare Royalty Partners, where he had been serving as chairperson since January 2013. Mr. Kozin has served as director of the Greenlight Fund, a non-profit focused on improving the lives of inner city children in families, since 2017.

Previously, Mr. Kozin served on the boards of directors of Isleworth Healthcare Acquisition Corporation, Endocyte (sold to Novartis), OvaScience, Inc (merged with Millendo Therapeutics), Dyax (sold to Shire), Frequency Therapeutics, Flex Pharma, Crunchtime! Information Systems, Medical Simulation Corporation, Brandwise, Lynx Therapeutics, Inc. Assurance Medical, Inc., and Dicerna (sold to Novo Nordisk). Mr. Kozin served as President of L.E.K. Consulting from 1997 through 2011 and as a senior Advisor from 2011 through 2018. Mr. Kozin received a Bachelor of Science degree in economics from Duke University and an MBA in finance from the Wharton School of the University of Pennsylvania.

Ms. Hudson has served as a director of the Company since June 2022. Currently, Ms. Hudson is the President and CEO of United Way Miami. Prior to this, she served as CEO of Chapman Partnership. Ms. Hudson serves as an executive Board Member and on the Governance Committee for MTF Biologics; as an Operating Advisor for Revival Healthcare Partners; and as a Board Member for Baxter Foundation.

From April 2016 to January 2018, Ms. Hudson was the President of Global Franchises and Innovation for ConvaTec, a $1.8 Billion international medical products and technologies company. From December 2013 to March 2016, Ms. Hudson served in various strategic leadership roles for Baxter, Inc., a company that develops, manufactures, and markets a broad portfolio of essential renal hospital products including home, acute and in-center dialysis; sterile IV solutions; and infusion systems and devices. Before joining Baxter, Ms. Hudson served as General Manager of Medication Management Systems, VP of Global Marketing for On-Market Product Strategies Devices, VP of Marketing – US Region Medication Management Systems, and VP of Continuous Improvement and Transformation, for Hospira, Inc (now Pfizer), a world leader in specialty generic injectable pharmaceuticals, generic acute-care and oncology injectables, integrated infusion therapy devices and medication management solutions.

Between August 1999 and February 2005, Ms. Hudson served in various leadership roles for Aon Corporation, a risk management, retail, reinsurance and wholesale brokerage, claims management, specialty services and human capital consulting services company; and Household International, a financial service provider of consumer loans, credit cards, auto finance and credit insurance products in the US, UK and Canada. Ms. Hudson holds a Master of Business Administration from Harvard Business School and a BS from Alabama A&M University. She was recognized as a Top 50 Business Leader of Color in 2015.

Mr. Oberdorf has served as a director of the Company since 2004. Currently, Mr. Oberdorf is Chief Executive Officer and Chairman of SIRVA, Inc., a leading global provider of moving and relocation services to corporations, consumers, and governments. From August 2010 through March 2011, Mr. Oberdorf consulted for Orchard Brands, a multi channel marketer of men’s and women’s apparel for the 55+ market segment. From December 2008 through August 2010, Mr. Oberdorf was Executive Vice President and Chief Financial Officer of infoGROUP, Inc., which provides business and consumer databases for sales leads and mailing lists, database marketing services, data processing services, e mail marketing, market research, and sales and marketing solutions. From June 2006 through 2008, Mr. Oberdorf was Senior Vice President, Chief Financial Officer and Treasurer of Getty Images Inc., the world’s leading creator and distributor of still imagery, footage and multi media products, as well as a recognized provider of other forms of premium digital content, including music.

From March 2002 through June 2006, Mr. Oberdorf was Senior Vice President, Chief Financial Officer and Treasurer of CMGI, Inc., a supply chain management, marketing distribution and ecommerce solutions company, where he served as a consultant from November 2001 through February 2002. From February 1999 through October 2001, Mr. Oberdorf was Senior Vice President and Chief Financial Officer of Bertelsmann AG’s subsidiary, BeMusic Direct, a direct to consumer music sales company. From January 1981 through January 1999, Mr. Oberdorf served in various capacities at Readers Digest Association, Inc., most recently as Vice President Global Books & Home Entertainment—Finance. Mr. Oberdorf has a Bachelor of Science degree in accounting from Boston College and an Executive MBA from the University of New Haven.